Patents
Literature
Hiro is an intelligent assistant for R&D personnel, combined with Patent DNA, to facilitate innovative research.
Hiro

536 results about "Psychogenic disease" patented technology

Psychogenic disease (or psychogenic illness) is a name given to physical illnesses that are believed to arise from emotional or mental stressors, or from psychological or psychiatric disorders. It is most commonly applied to illnesses where a physical abnormality or other biomarker has not yet been identified. In the absence of such "biological" evidence of an underlying disease process, it is often assumed that the illness must have a psychological cause, even if the patient shows no indications of being under stress or of having a psychological or psychiatric disorder. Examples of diseases that are believed by many to be psychogenic include psychogenic seizures, psychogenic polydipsia, psychogenic tremor, and psychogenic pain.

Apparatus and method for closed-loop intracranial stimulation for optimal control of neurological disease

A neurological control system for modulating activity of any component or structure comprising the entirety or portion of the nervous system, or any structure interfaced thereto, generally referred to herein as a “nervous system component.” The neurological control system generates neural modulation signals delivered to a nervous system component through one or more intracranial (IC) stimulating electrodes in accordance with treatment parameters. Such treatment parameters may be derived from a neural response to previously delivered neural modulation signals sensed by one or more sensors, each configured to sense a particular characteristic indicative of a neurological or psychiatric condition.
Owner:CYBERONICS INC

Closed-loop feedback-driven neuromodulation

A neurological control system for modulating activity of any component or structure comprising the entirety or portion of the nervous system, or any structure interfaced thereto, generally referred to herein as a “nervous system component.” The neurological control system generates neural modulation signals delivered to a nervous system component through one or more neuromodulators, comprising intracranial (IC) stimulating electrodes and other actuators, in accordance with treatment parameters. Such treatment parameters may be derived from a neural response to previously delivered neural modulation signals sensed by one or more sensors, each configured to sense a particular characteristic indicative of a neurological or psychiatric condition.
Owner:LIVANOVA USA INC

Apparatus and method for closed-loop intracranial stimulation for optimal control of neurological disease

InactiveUS20070073355A1Reducing time and number of interactionSatisfactory treatmentHead electrodesImplantable neurostimulatorsIntracranial stimulationNervous system
A neurological control system for modulating activity of any component or structure comprising the entirety or portion of the nervous system, or any structure interfaced thereto, generally referred to herein as a “nervous system component.” The neurological control system generates neural modulation signals delivered to a nervous system component through one or more intracranial (IC) stimulating electrodes in accordance with treatment parameters. Such treatment parameters may be derived from a neural response to previously delivered neural modulation signals sensed by one or more sensors, each configured to sense a particular characteristic indicative of a neurological or psychiatric condition.
Owner:CYBERONICS INC

Monitoring efficacy of neural modulation therapy

A neurological control system for modulating activity of any component or structure comprising the entirety or portion of the nervous system, or any structure interfaced thereto, generally referred to herein as a “nervous system component.” The neurological control system generates neural modulation signals delivered to a nervous system component through one or more neuromodulators to control neurological state and prevent neurological signs and symptoms. Such treatment parameters may be derived from a neural response to previously delivered neural modulation signals sensed by one or more sensors, each configured to sense a particular characteristic indicative of a neurological or psychiatric condition.
Owner:CYBERONICS INC

Method and system for modulating the vagus nerve (10th cranial nerve) with electrical pulses using implanted and external componants, to provide therapy for neurological and neuropsychiatric disorders

A method and system for neuromodulating vagus nerve(s) to provide therapy for neurological and neuropsychiatric disorders comprises implantable and external components. The pulsed electrical stimulation to vagus nerve(s) is used for disorders such as epilepsy, depression, anxiety disorders, neurogenic pain, compulsive eating disorders, obesity, dementia including Alzheimer's disease, and migraines. The pulsed electrical stimulation to vagus nerve(s) may be provided using one of the following stimulation systems, such as: a) an implanted stimulus-receiver with an external stimulator; b) an implanted stimulus-receiver comprising a high value capacitor for storing charge, used in conjunction with an external stimulator; c) a programmer-less implantable pulse generator (IPG) which is operable with a magnet; d) a programmable implantable pulse generator; e) a combination implantable device comprising both a stimulus-receiver and a programmable IPG; and f) an IPG comprising a rechargeable battery. In one embodiment, the external components such as the programmer or external stimulator may comprise a telemetry means for networking. The telemetry means therefore allows for interrogation or programming of implanted device, from a remote location over a wide area network.
Owner:NEURO & CARDIAC TECH

Methods and systems for predicting future symptomatology in a patient suffering from a neurological or psychiatric disorder

InactiveUS7277758B2Reducing time and number of interactionSatisfactory treatmentHead electrodesExternal electrodesDiseaseNervous system
A neurological control system for modulating activity of any component or structure comprising the entirety or portion of the nervous system, or any structure interfaced thereto, generally referred to herein as a “nervous system component.” The neurological control system generates neural modulation signals delivered to a nervous system component through one or more intracranial (IC) stimulating electrodes in accordance with treatment parameters. Such treatment parameters may be derived from a neural response to previously delivered neural modulation signals sensed by one or more sensors, each configured to sense a particular characteristic indicative of a neurological or psychiatric condition.
Owner:CYBERONICS INC

Apparatus and method for closed-loop intracranial stimulation for optimal control of neurological disease

A neurological control system for modulating activity of any component or structure comprising the entirety or portion of the nervous system, or any structure interfaced thereto, generally referred to herein as a “nervous system component.” The neurological control system generates neural modulation signals delivered to a nervous system component through one or more intracranial (IC) stimulating electrodes in accordance with treatment parameters. Such treatment parameters may be derived from a neural response to previously delivered neural modulation signals sensed by one or more sensors, each configured to sense a particular characteristic indicative of a neurological or psychiatric condition.
Owner:CYBERONICS INC

Methods and systems for determining subject-specific parameters for a neuromodulation therapy

A neurological control system for modulating activity of any component or structure comprising the entirety or portion of the nervous system, or any structure interfaced thereto, generally referred to herein as a “nervous system component.” The neurological control system generates neural modulation signals delivered to a nervous system component through one or more neuromodulators to control neurological state and prevent neurological signs and symptoms. Such treatment parameters may be derived from a neural response to previously delivered neural modulation signals sensed by one or more sensors, each configured to sense a particular characteristic indicative of a neurological or psychiatric condition.
Owner:CYBERONICS INC

Novel Thieno-Pyridine and Thieno-Pyrimidine Derivatives and Their Use as Positive Allosteric Modulators of Mglur2-Receptors

The present invention relates to novel compounds, in particular novel thieno-pyridine and thieno-pyrimidine derivatives according to Formula (I), wherein all radicals are defined in the application. The compounds according to the invention are positive allosteric modulators of metabotropic receptors-subtype 2 ("mGluR2") which are useful for the treatment or prevention of neurological and psychiatric disorders associated with glutamate dysfunction and diseases in which the mGluR2 subtype of metabotropic receptors is involved. In particular, such diseases are central nervous system disorders selected from the group of anxiety, schizophrenia, migraine, depression, and epilepsy. The invention is also directed to pharmaceutical compositions and processes to prepare such compounds and compositions, as well as to the use of such compounds for the prevention and treatment of such diseases in which mGluR2 is involved.
Owner:ORTHO MCNEIL JANSSEN PHARMA

Magnetic Stimulating Circuit For Nervous Centralis System Apparatus, Purpose, and Method Thereof

A magnetic stimulation apparatus for central nervous system and circuit thereof and use of the apparatus and method of using the apparatus are shown. Controlling circuit design and outputting wave form signal to a drive power supply circuit enables the drive power supply circuit to output current of corresponding wave form to coils, and by means of the design of the shape, number of turns, size, interval of the coils, generates within a certain region inside the coils a desired time-variant magnetic field which is then applied to the brain of an animal or a human being so that the central nervous system can receive a wide area synergy magnetic stimulation with a precise wave form, high frequency or a combination of a plurality of frequency components, thus achieving the treatment of nervous and psychiatric diseases or brain function improvement in combination with behavior guidance, thought guidance, or psychological guidance.
Owner:ZHENG YUNFENG

Combination therapy for depression, prevention of suicide, and various medical and psychiatric conditions

InactiveUS7973043B2Preventing disease progression/modifyingDelaying/preventing relapseBiocideNervous disorderInitial treatmentTherapy resistant
The present invention relates to a new method of treatment for persons meeting diagnoses for major depressive disorder, or other unipolar (non-bipolar, non-psychotic and non-treatment resistant) depression. The method comprises administering a combination of two categories of drugs, antipsychotics or dopamine system stabilizers, in combination with a newer antidepressant such as a selective serotonin reuptake inhibitor, as initial treatment or as soon as possible. The method targets the prevention of suicide, and provides other benefits including preventing disease progression development of tolerance toward the antidepressants. Another aspect of the invention relates to using the method for alleviating cognitive distortion and related functional impairment or health risks, and / or using the method for smoking cessation or nicotine withdrawal.
Owner:MIGALY PETER

Responsive therapy for psychiatric disorders

An implantable neurostimulator system for treating psychiatric disorders includes scheduled and responsive therapy capabilities including responsive stimulation applied to the cingulate gyrus of the brain. Methods for treating depression, bipolar disorder, anxiety and obsessive-compulsive disorders, post-traumatic stress disorder, addiction, schizophrenia, and autism and other developmental disorders employ an inventive system to advantageously reduce symptoms and address underlying causes of the disorders.
Owner:NEUROPACE

Foamable compositions, kits and methods for hyperhidrosis

ActiveUS20070253911A1Ameliorating and reducing perspirationExcessive hyperhidrosisCosmetic preparationsBiocideDiseasePlantar hyperhidrosis
The composition of the present invention is geared towards treating hyperhidrosis or any condition involving and / or promoting excessive sweating, typically involving the whole body, include hyperthyroidism or similar endocrine disorders; endocrine treatment for prostatic cancer or other types of malignant disorder; severe psychiatric disorders; obesity and menopause. The foamable composition of the present invention is suitable for treating palmar hyperhidrosis; axillary hyperhidrosis; plantar hyperhidrosis; hyperhidrosis of the trunk and / or the thighs; and facial hyperhidrosis; and any combination of them consisting of a therapeutic foamable composition including: an active agent, suitable for the treatment or prevention of hyperhidrosis.
Owner:VYNE THERAPEUTICS INC

Multiple lead method for deep brain stimulation

New methods for deep brain stimulation (DBS) surgery using two or more electrical leads are provided. The methods are useful for treating a wide variety of brain-associated disorders including movement-related disorders, psychiatric disorders, metabolic / eating disorders, memory disorders, and pain. Methods featuring stimulation of distinct target areas of a subject's brain, such as the thalamic ventralis intermedius (VIM) and the ventralis oralis (VOA / VOP) using multiple electrical leads for treatment of tremor provide superior clinical outcomes to stimulation with single leads implanted in these target areas.
Owner:UNIV OF FLORIDA RES FOUNDATION INC

Apparatus for autonomic neuromodulation for the treatment of systemic disease

InactiveUS20100241183A1Delay is slowPreserving and prolonging effect of modulationSpinal electrodesUltrasound therapyNervous systemEfferent
A method, apparatus, and surgical technique for the modulation of autonomic function, for the purpose of treating any of several conditions and diseases, including obesity, metabolic disorders, endocrine disorders, diabetes, respiratory disease, asthma, inflammatory disease, immunological disease, infection, cancer, cardiac disease, cardiovascular disease, cerebrovascular disease, stroke, vasospasm, vascular disease, psychiatric disease, depression, affective disorders, anxiety disorders, and other conditions. This includes neural and tissue modulators, including implanted devices, used to modulate efferent and afferent autonomic neurons to influence or control autonomic or other neural function, including modulation of sympathetic and parasympathetic nervous system components as well as their combination.
Owner:DILORENZO BIOMEDICAL

BENZAMIDE mGluR5 POSITIVE ALLOSTERIC MODULATORS AND METHODS OF MAKING AND USING SAME

InactiveUS20090042855A1Increase awarenessPotentiate metabotropic glutamate receptor activityBiocideNervous disorderAllosteric modulatorMetabotropic glutamate receptor
In one aspect, the invention relates to compounds, including phenylethynylbenzamide derivatives, cycloalkylethynylbenzamide derivatives, styrylbenzamide derivatives, 4-(3-phenyl-1,2,4-oxadiazol-5-yl)benzamide derivatives, 4-(pyridinylethynyl)benzamide derivatives, and N1-phenylterephthalamide derivatives, which are useful as positive allosteric modulators of the metabotropic glutamate receptor subtype 5 (mGluR5); synthetic methods for making the compounds; pharmaceutical compositions comprising the compounds; and methods of treating neurological and psychiatric disorders associated with glutamate dysfunction using the compounds and compositions. This abstract is intended as a scanning tool for purposes of searching in the particular art and is not intended to be limiting of the present invention.
Owner:VANDERBILT UNIV

Transgenic animal model for modelling pathological anxiety, a method for identifying compounds for treatment of diseases or disorders caused by pathological anxiety and a method for using wfs1 protein as a target for identifying effective compounds against pathological anxiety

The invention discloses the transgenic animal model for pathological anxiety, the method to generate this model, the method to test drugs and drug candidates for the treatment of pathological anxiety and the method to use Wfs1 as target for screening of new anxiolytic drugs to treat pathological anxiety. This animal model is useful to test potential drug candidates for the treatment of diseases caused by pathological anxiety and to screen therapeutic compounds for the psychiatric disorders caused by reduces stress-tolerance and deficiency in adaptation to environmental challenges.
Owner:TARTU ULIKOOL THE UNIV OF TARTU

Foamable Compositions, Kits and Methods for Hyperhidrosis

InactiveUS20120156144A1Antibacterial agentsCosmetic preparationsDiseasePlantar hyperhidrosis
The composition of the present invention is geared towards treating hyperhidrosis or any condition involving and / or promoting excessive sweating, typically involving the whole body, include hyperthyroidism or similar endocrine disorders; endocrine treatment for prostatic cancer or other types of malignant disorder; severe psychiatric disorders; obesity and menopause. The foamable composition of the present invention is suitable for treating palmar hyperhidrosis; axillary hyperhidrosis; plantar hyperhidrosis; hyperhidrosis of the trunk and / or the thighs; and facial hyperhidrosis; and any combination of them consisting of a therapeutic foamable composition including: an active agent, suitable for the treatment or prevention of hyperhidrosis.
Owner:FOAMIX PHARMACEUTICALS LIMITED

Responsive therapy for psychiatric disorders

An implantable neurostimulator system for treating psychiatric disorders includes scheduled and responsive therapy capabilities including responsive stimulation applied to the cingulate gyrus of the brain. Methods for treating depression, bipolar disorder, anxiety and obsessive-compulsive disorders, post-traumatic stress disorder, addiction, schizophrenia, and autism and other developmental disorders employ an inventive system to advantageously reduce symptoms and address underlying causes of the disorders.
Owner:NEUROPACE

Piperazine-substituted benzothiophenes for treatment of mental disorders

The present invention provides a heterocyclic compound represented by the general formula (1): The compound of the present invention has a wide treatment spectrum for mental disorders including central nervous system disorders, no side effects and high safety.
Owner:OTSUKA PHARM CO LTD

Seizure therapy method and apparatus

The invention provides a method for treating a patient for mental illnesses, such as depression, by applying a magnetic field to the patient, producing a seizure in the patient as a function of a strength of the magnetic field, and preventing further stimulation from the magnetic field when the seizure is in progress. Such Magnetic Seizure Therapy (MST) does not include many of the known side effects of electroconvulsive therapy (ECT).
Owner:NEURONETICS

Foamable compositions, kits and methods for hyperhidrosis

ActiveUS8119109B2BiocideCosmetic preparationsDiseasePlantar hyperhidrosis
The composition of the present invention is geared towards treating hyperhidrosis or any condition involving and / or promoting excessive sweating, typically involving the whole body, include hyperthyroidism or similar endocrine disorders; endocrine treatment for prostatic cancer or other types of malignant disorder; severe psychiatric disorders; obesity and menopause. The foamable composition of the present invention is suitable for treating palmar hyperhidrosis; axillary hyperhidrosis; plantar hyperhidrosis; hyperhidrosis of the trunk and / or the thighs; and facial hyperhidrosis; and any combination of them consisting of a therapeutic foamable composition including: an active agent, suitable for the treatment or prevention of hyperhidrosis.
Owner:VYNE THERAPEUTICS INC

Transcranial magnet stimulation of deep brain targets

The treatment of specific neurological and psychiatric illnesses using Transcranial Magnetic Stimulation (TMS) requires that specific neuroanatomical structures are targeted using specific pulse parameters. Described herein are methods of positioning and powering TMS electromagnets to selectively stimulate a deep brain target region while minimizing the impact on non-target regions between the TMS electromagnet and the target. Use of these configurations may involve a combination of physical, spatial and / or temporal summation. Specific approaches to achieving temporal summation are detailed.
Owner:BRAINSWAY

Low level light therapy for enhancement of neurologic function

Therapeutic methods for enhancing neurologic function such as may be desired in individuals having motor and / or cognitive impairment, including that resulting from Alzheimer's disease, dementia, head trauma, mental disease such as depression, stroke and neurodegeneration, as well as in healthy individuals are described, the methods including delivering a cognitive enhancing effective amount of light energy having a wavelength in the visible to near-infrared wavelength range to a target area of the brain. The neurologic function enhancing effective amount of light energy, in accordance with a preferred embodiment, is a predetermined power density (mW / cm2) at the level of the brain tissue being treated, and is delivered by determining a surface power density of the light energy that is sufficient to deliver the predetermined power density of light energy to the target brain tissue. In one embodiment, progenitor cells are treated using light energy and implanted into the central nervous system of a patient.
Owner:PHOTOTHERA IP HLDG

Selective opioid compounds

ActiveUS20090209569A1Reducing lipid permeability of drugReduce penetrationAntibacterial agentsBiocideDiseaseInterstitial cystitis
The present invention relates to compounds of Formula I or II, or pharmaceutically acceptable salts, esters, or prodrugs thereof:which relates to morphinan compounds useful as μ, δ, and / or κ receptor opioid compounds and pharmaceuticals containing same that may be useful for mediating analgesia, combating drug addiction, alcohol addiction, drug overdose, mental illness, bladder dysfunctions, neurogenic bladder, interstitial cystitis, urinary incontinence, premature ejaculation, inflammatory pain, peripherally mediated and neuropathic pain, cough, lung edema, diarrhea, cardiac disorders, cardioprotection, depression, and cognitive, respiratory, diarrhea, irritable bowel syndrome and gastro-intestinal disorders, immunomodulation, and anti-tumor agents.
Owner:ALKERMES INC

Device and method of phase-locking brain stimulation to electroencephalographic rhythms

InactiveUS20160220836A1ElectroencephalographyElectrotherapyDiseaseBrain rhythm
The device and method for phase-locking brain stimulation to electroencephalographic rhythms improves the accuracy, specificity, and effectiveness of non-invasive brain stimulation devices by timing pulses of brain stimulation to occur in synchrony with naturally occurring brain rhythms measured at the scalp of a patient in order to treat an assortment of neurological and psychiatric conditions. The device and method provided herein improve non-invasive brain stimulation techniques by time-locking the onset of brain stimulation to the phase of naturally-occurring rhythmic oscillations of brain activity that can be recorded with electroencephalography (EEG). The device and method perform real-time signal analysis of a specified EEG rhythm, extract frequency-domain phase information to estimate the next occurrence of a desired EEG rhythm phase, and trigger a brain stimulation pulse so as to align precisely with this predicted EEG phase.
Owner:THE BOARD OF TRUSTEES OF THE UNIV OF ARKANSAS

Method and apparatus for computer modeling of the interaction between and among cortical and subcortical areas in the human brain for the purpose of predicting the effect of drugs in psychiatric and cognitive diseases

Computer modeling of interactions between and among cortico and subcortical areas of the human brain, for example in a normal and a pathological state resembling schizophrenia which pathological state has inputs representing the effects of a drug(s), for the purpose of using the outputs to predict the effect of drugs in psychiatric and cognitive diseases on one or more clinical scales. Diseases that can be modeled include psychiatric disorders, such as schizophrenia, bipolar disorder, major depression, ADHD, autism, obsessive-compulsive disorder, substance abuse and cognitive deficits therein and neurological disorders such as Alzheimer's disease, Mild Cognitive impairment, Parkinson's disease, stroke, vascular dementia, Huntington's disease, epilepsy and Down syndrome. The computer model preferably uses the biological state of interactions between and among cortico and subcortical areas of the human brain, to define the biological processes related to the biological state of the generic synapse model, the striatum, Locus Coeruleus, Dorsal raphe, hippocampus, amygdala and cortex, as well as certain mathematical relationships related to interactions among biological variables associated with the biological processes.
Owner:CERTARA USA INC
Who we serve
  • R&D Engineer
  • R&D Manager
  • IP Professional
Why Patsnap Eureka
  • Industry Leading Data Capabilities
  • Powerful AI technology
  • Patent DNA Extraction
Social media
Patsnap Eureka Blog
Learn More
PatSnap group products